Literature DB >> 21710489

Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor.

Michelle M Duffy1, Jana Pindjakova, Shirley A Hanley, Cathal McCarthy, Gudrun A Weidhofer, Eva M Sweeney, Karen English, Georgina Shaw, J Mary Murphy, Frank P Barry, Bernard P Mahon, Orina Belton, Rhodri Ceredig, Matthew D Griffin.   

Abstract

Mesenchymal stem cells (MSCs) inhibit T-cell activation and proliferation but their effects on individual T-cell-effector pathways and on memory versus naïve T cells remain unclear. MSC influence on the differentiation of naïve and memory CD4(+) T cells toward the Th17 phenotype was examined. CD4(+) T cells exposed to Th17-skewing conditions exhibited reduced CD25 and IL-17A expression following MSC co-culture. Inhibition of IL-17A production persisted upon re-stimulation in the absence of MSCs. These effects were attenuated when cell-cell contact was prevented. Th17 cultures from highly purified naïve- and memory-phenotype responders were similarly inhibited. Th17 inhibition by MSCs was reversed by indomethacin and a selective COX-2 inhibitor. Media from MSC/Th17 co-cultures contained increased prostaglandin E2 (PGE2) levels and potently suppressed Th17 differentiation in fresh cultures. MSC-mediated Th17 inhibition was reversed by a selective EP4 antagonist and was mimicked by synthetic PGE2 and a selective EP4 agonist. Activation-induced IL-17A secretion by naturally occurring, effector-memory Th17 cells from a urinary obstruction model was also inhibited by MSC co-culture in a COX-dependent manner. Overall, MSCs potently inhibit Th17 differentiation from naïve and memory T-cell precursors and inhibit naturally-occurring Th17 cells derived from a site of inflammation. Suppression entails cell-contact-dependent COX-2 induction resulting in direct Th17 inhibition by PGE2 via EP4.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21710489     DOI: 10.1002/eji.201141499

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  89 in total

Review 1.  Multipotent mesenchymal stromal cells and the innate immune system.

Authors:  Katarina Le Blanc; Dimitrios Mougiakakos
Journal:  Nat Rev Immunol       Date:  2012-04-25       Impact factor: 53.106

2.  Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation.

Authors:  Aideen E Ryan; Paul Lohan; Lisa O'Flynn; Oliver Treacy; Xizhe Chen; Cynthia Coleman; Georgina Shaw; Mary Murphy; Frank Barry; Matthew D Griffin; Thomas Ritter
Journal:  Mol Ther       Date:  2013-11-01       Impact factor: 11.454

Review 3.  Mesenchymal stem cells: a friend or foe in immune-mediated diseases.

Authors:  Marina Gazdic; Vladislav Volarevic; Nebojsa Arsenijevic; Miodrag Stojkovic
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

Review 4.  The influence of macrophages on mesenchymal stromal cell therapy: passive or aggressive agents?

Authors:  F Carty; B P Mahon; K English
Journal:  Clin Exp Immunol       Date:  2017-02-20       Impact factor: 4.330

Review 5.  Harnessing the mesenchymal stem cell secretome for regenerative urology.

Authors:  Daniel Z Sun; Benjamin Abelson; Paurush Babbar; Margot S Damaser
Journal:  Nat Rev Urol       Date:  2019-06       Impact factor: 14.432

Review 6.  Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells.

Authors:  Antoine Monsel; Ying-Gang Zhu; Stephane Gennai; Qi Hao; Jia Liu; Jae W Lee
Journal:  Anesthesiology       Date:  2014-11       Impact factor: 7.892

7.  Mesenchymal Stem Cells Attenuate NADPH Oxidase-Dependent High Mobility Group Box 1 Production and Inhibit Abdominal Aortic Aneurysms.

Authors:  Ashish K Sharma; Morgan D Salmon; Guanyi Lu; Gang Su; Nicolas H Pope; Joseph R Smith; Mark L Weiss; Gilbert R Upchurch
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03-17       Impact factor: 8.311

8.  The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus.

Authors:  Dandan Wang; Saisai Huang; Xinran Yuan; Jun Liang; Renju Xu; Genhong Yao; Xuebing Feng; Lingyun Sun
Journal:  Cell Mol Immunol       Date:  2015-10-05       Impact factor: 11.530

9.  Synergistic and Superimposed Effect of Bone Marrow-Derived Mesenchymal Stem Cells Combined with Fasudil in Experimental Autoimmune Encephalomyelitis.

Authors:  Jing-Wen Yu; Yan-Hua Li; Guo-Bin Song; Jie-Zhong Yu; Chun-Yun Liu; Jian-Chun Liu; Hai-Fei Zhang; Wan-Fang Yang; Qing Wang; Ya-Ping Yan; Bao-Guo Xiao; Cun-Gen Ma
Journal:  J Mol Neurosci       Date:  2016-08-30       Impact factor: 3.444

Review 10.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.